Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

497

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26/26/26	CN¥59.21	-6.87%	19,13,933
25/26/25	CN¥63.58	+0.89%	17,25,341
24/26/24	CN¥63.02	-5.18%	13,39,500
23/26/23	CN¥66.46	+1.71%	11,58,600
22/26/22	CN¥65.34	-2.64%	14,65,497

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 26/06/2026			5-day change	1st Jan Change
59.21 ^CNY	-6.87%		-11.77%	-0.77%

28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	467.5Cr 69Cr 60Cr 56Cr 52Cr 98Cr 6.48TCr 100Cr 667.59Cr 258.32Cr 3.2TCr 258.06Cr 252.42Cr 11TCr	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	484Cr 71Cr 62Cr 58Cr 54Cr 100.95Cr 6.71TCr 103.05Cr 691.16Cr 267.44Cr 3.32TCr 267.17Cr 261.33Cr 12TCr	EV / Sales 2024	6.46x	EV / Sales 2025	31.6x
Free-Float	31.21%	Yield 2024 *	-	Yield 2025	-

28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
27/02	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
24/02	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
21/01	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI
05/12	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.	CI
23/25/23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
13/25/13	Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million.	CI
29/25/29	Duorui Pharma Expects Control Change Amid Parents' Plan	MT
29/25/29	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2025.	CI

1 day	-6.87%
1 week	-11.77%
Current month	-20.62%
1 month	-26.17%
3 months	-26.49%
6 months	+12.33%
Current year	-0.77%

Tibet Duo Rui Pharmaceutical Co., Ltd. Share Price

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news : Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	58	67.74
1 month	58	80.89
Current year	54.9	98.29
1 year	28.09	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	01/12/2018
Chao Li DFI	Director of Finance/CFO	47	01/05/2017
Fen Jin DFI	Director of Finance/CFO	46	01/12/2017

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	01/12/2017
Shao Zhong Zhang BRD	Director/Board Member	70	21/02/2020
Qin Deng BRD	Director/Board Member	58	21/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-6.87%	-11.77%	+102.64%	+159.69%	74Cr
ELI LILLY AND COMPANY	+7.00%	+9.05%	+51.14%	+165.43%	1,00600Cr
JOHNSON & JOHNSON	+3.48%	+9.54%	+66.67%	+54.83%	59TCr
ABBVIE INC.	+1.37%	+7.18%	+31.98%	+82.68%	43TCr
ROCHE HOLDING AG	-0.66%	+5.11%	+29.26%	+21.27%	33TCr
ASTRAZENECA PLC	+1.82%	+8.19%	+41.15%	+26.80%	29TCr
NOVARTIS AG	+0.22%	+6.75%	+31.51%	+42.02%	28TCr
NOVO NORDISK A/S	+0.73%	+8.53%	-26.22%	-40.85%	21TCr
AMGEN INC.	+0.98%	+3.51%	+27.85%	+58.78%	19TCr
GILEAD SCIENCES, INC.	+2.42%	+1.55%	+17.82%	+65.62%	15TCr
Average	+0.94%	+4.42%	+37.38%	+63.63%	34.87TCr
Weighted average by Cap.	+2.99%	+5.37%	+39.44%	+78.48%

	2024	2025
Net sales	24Cr 3.54Cr 3.1Cr 2.86Cr 2.68Cr 5.02Cr 333.69Cr 5.12Cr 34Cr 13Cr 164.92Cr 13Cr 13Cr 571.85Cr	15Cr 2.27Cr 1.99Cr 1.83Cr 1.71Cr 3.22Cr 213.8Cr 3.28Cr 22Cr 8.52Cr 105.67Cr 8.51Cr 8.32Cr 366.4Cr
Net income	-6.27Cr -92.12L -80.77L -74.45L -69.7L -1.31Cr -87Cr -1.33Cr -8.95Cr -3.46Cr -43Cr -3.46Cr -3.38Cr -148.93Cr	-10Cr -1.5Cr -1.32Cr -1.21Cr -1.14Cr -2.13Cr -141.68Cr -2.18Cr -15Cr -5.65Cr -70Cr -5.64Cr -5.52Cr -242.81Cr
Net Debt	13Cr 1.98Cr 1.74Cr 1.6Cr 1.5Cr 2.81Cr 186.77Cr 2.87Cr 19Cr 7.44Cr 92Cr 7.43Cr 7.27Cr 320.08Cr	17Cr 2.43Cr 2.13Cr 1.96Cr 1.84Cr 3.44Cr 228.85Cr 3.51Cr 24Cr 9.12Cr 113.1Cr 9.11Cr 8.91Cr 392.2Cr